Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Regulatory News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 290.00
Bid: 300.00
Ask: 310.00
Change: -7.00 (-2.36%)
Spread: 10.00 (3.333%)
Open: 300.00
High: 290.00
Low: 290.00
Prev. Close: 297.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Preclinical Results at ASGCT Annual Meeting

21 May 2018 07:00

RNS Number : 6263O
MaxCyte, Inc.
21 May 2018
 

 

 

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

MaxCyte Reports Preclinical Results at ASGCT Annual Meeting Showing Correction of Sickle Cell Disease Mutation in Hematopoietic Stem Cells

 

- Data demonstrate the potential of MaxCyte's technologies in non-viral CRISPR gene correction for the treatment of sickle cell disease

 

Gaithersburg, Maryland - 21 May 2018: MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life sciences company, today announced that preclinical data for its non-viral CRISPR-mediated gene-correction of sickle cell mutation in hematopoietic stem cells (HSC) from a sickle cell disease (SCD) patient were presented at the annual meeting of the American Society of Gene and Cell Therapy (ASGCT) in Chicago on Friday, 18 May 2018.

 

The new data were presented in a poster presentation, entitled "GMP-compliant non-viral CRISPR-mediated process correcting the sickle cell disease mutation in SCD patient CD34+ cells achieves 60% wild type adult hemoglobin expression in differentiated erythrocytes." The data from work with the National Institutes of Health's (NIH) National Heart Lung and Blood Institute (NHLBI) demonstrated the potential of MaxCyte's technologies and the non-viral CRISPR gene correction in the treatment of SCD.

 

"We're encouraged that MaxCyte's technology is at the forefront of enabling non-viral CRISPR-mediated correction of disease mutations at clinically-relevant levels," said Doug Doerfler, MaxCyte Chief Executive Officer. "We're excited by these results for their potential to bring therapeutic benefit to individuals living with SCD."

 

The abstract can be found at the ASGCT meeting website at annualmeetingasgct.com/am18/abstracts and the presentation is available via https://www.maxcyte.com/resource-center/posters-presentations/.

 

About Sickle Cell Disease

 

According to the NHLBI, sickle cell disease (SCD) describes a group of inherited red blood cell disorders. Patients with SCD have abnormal hemoglobin, called hemoglobin S or sickle hemoglobin, in their red blood cells. Hemoglobin is a protein in red blood cells that carries oxygen throughout the body. Those who have SCD inherit two abnormal hemoglobin genes, one from each parent. In all forms of SCD, at least one of the two abnormal genes cause a person's body to make hemoglobin S.

 

Sickle cell disease is a life-long illness. The severity of the disease varies widely from person to person. In high-income countries like the United States, according to NHLBI, the life expectancy of a person with SCD is now about 40-60 years. Currently, hematopoietic stem cell transplantation (HSCT) is the only cure for SCD. Unfortunately, most people with SCD are either too old for a transplant or don't have a relative who is a good enough genetic match for them to act as a donor. A well-matched donor is needed to have the best chance for a successful transplant. While there are some treatments that can reduce symptoms and prolong life, more medical options are needed.

 

About MaxCyte

MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® Technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immuno-oncology. The Company has placed its cutting-edge flow electroporation instruments worldwide, including with nine of the top ten global biopharmaceutical companies, and has more than 50 partnered programme licences in cell therapy including more than 20 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products.

 

 For more information, visit www.maxcyte.com.

 

 

###

 

For further information, please contact:

 

MaxCyte Inc.

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer

 

+1 301 944 1660

Nominated Adviser and Broker

Panmure Gordon

Freddy Crossley

Emma Earl

Ryan McCarthy

James Stearns

 

 

+44 (0)20 7886 2500

Financial PR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

Sukaina Virji

 

+44 (0)203 709 5700

maxcyte@consilium-comms.com

 
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRABSGDULDBBGII
Date   Source Headline
11th Nov 20217:00 amRNSMaxCyte Reports Third Quarter Financial Results
3rd Nov 20211:00 pmRNSAppointment of Chairman of the Board
29th Oct 20215:01 pmRNSResult of AGM
28th Oct 20213:00 pmRNSLicense with Nkarta, Inc.
26th Oct 20217:00 amRNSNotice of Results
6th Oct 20217:00 amRNSHoldings in Company
1st Oct 20213:49 pmRNSNotice of AGM and Change of Director
1st Oct 202112:36 pmRNSTotal Voting Rights
17th Sep 20212:35 pmRNSMaxCyte Set to Join Russell 2000® Index
14th Sep 20217:00 amRNSHalf-year Report
14th Sep 20217:00 amRNSFiling of Form 10-Q
2nd Sep 20212:26 pmRNSNotice of Results
10th Aug 20217:00 amRNSGrant of Options
9th Aug 20217:00 amRNSLicense with Sana Biotechnology
5th Aug 20214:05 pmRNSAmendments to Bylaws
3rd Aug 20213:51 pmRNSClosing of Offering
2nd Aug 20217:00 amRNSFull Exercise of Over-Allotment Option
30th Jul 20214:43 pmRNSSecond Price Monitoring Extn
30th Jul 20214:36 pmRNSPrice Monitoring Extension
30th Jul 20217:00 amRNSPricing of Offering and Approval to List on Nasdaq
26th Jul 202111:14 amRNSLaunch of Offering and Application to List
19th Jul 202112:30 pmRNSTermination of DI facility and transition to CDI
12th Jul 20217:00 amRNSS-1 Financial information & Directorate Change
12th Jul 20217:00 amRNSPublic Filing of Registration Statement with SEC
6th Jul 20215:36 pmRNSResult of Special Meeting
16th Jun 20217:01 amRNSPublication of Annual Report and Accounts
16th Jun 20217:00 amRNSStockholder Circular and Notice of Special Meeting
15th Jun 20217:00 amRNSMaxcyte Appoints Two New Non-Executive Directors
2nd Jun 20219:18 amRNSTotal Voting Rights
25th May 20217:00 amRNSSigning of Strategic Platform Licence
14th May 20217:00 amRNSProposed Dual-Listing on Nasdaq
13th May 20217:00 amRNSConsolidation of Trading Lines
20th Apr 20217:00 amRNSFull Year Results
15th Apr 20217:00 amRNSNotice of Full Year Results
1st Apr 20217:00 amRNSTotal Voting Rights
11th Mar 20213:01 pmRNSHolding(s) in Company
3rd Mar 20217:00 amRNSTotal Voting Rights
23rd Feb 20217:00 amRNSParticipation in Upcoming Investor Conferences
19th Feb 20217:00 amRNSDirector Dealings and Issue of Equity
17th Feb 20215:44 pmRNSGrant of Options
15th Feb 20214:32 pmRNSHolding(s) in Company
12th Feb 20211:59 pmRNSHolding(s) in Company
8th Feb 20212:59 pmRNSHolding(s) in Company
5th Feb 20219:01 amRNSPrice Monitoring Extension
4th Feb 20217:00 amRNSDirector Dealings and Issue of Equity
4th Feb 20217:00 amRNSCORRECTION: MaxCyte Announces £40m Subscription
3rd Feb 20214:36 pmRNSMaxCyte Announces £40 million Subscription
3rd Feb 20214:35 pmRNSAppointment of Joint Corporate Broker
21st Jan 20212:49 pmRNSIncrease to Block Listing
20th Jan 20217:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.